Form 4: Lyell Immunopharma Director Otis Brawley Acquires 130,000 Stock Options

Director Otis Brawley acquired 130,000 stock options in Lyell Immunopharma, Inc. on June 14, 2024.

Summary

• On June 14, 2024, Otis W. Brawley, a director of Lyell Immunopharma, Inc., acquired 130,000 stock options.
• The exercise price of these options is $2.36.
• The options vest on the earlier of the next annual meeting of stockholders following June 14, 2024, or the first anniversary of that date, contingent upon continuous service.
• The options expire on June 13, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which doesn't inherently indicate positive or negative sentiment, but the director's acquisition could be interpreted as a slightly positive signal.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, common in publicly traded companies within the biotechnology and pharmaceutical industries.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies, particularly in the biotech industry, to align their interests with those of shareholders.
• The vesting schedule and exercise price are typical for such grants, often tied to continued service and market conditions.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates